7 December 2015 - CADTH has received notice of a pending submission from Sanofi for Praluent (alirocumab) for use by patients with primary hypercholesterolemia (non-familial or heterozygous familial) or mixed dyslipidaemia.

For more details, go to: https://www.cadth.ca/alirocumab